deoxynucleotidyltransferase terminal interacting protein 1Genealiases: C20orf167 · Tdif1 · dJ447F3.4
Q-omics provides the consensus-scored DNTTIP1 profile across patient tissues and cancer cell-line models. DNTTIP1 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, DNTTIP1 is differentially expressed in 16, with the highest sampling consensus in HNSC. Additionally, DNTTIP1 protein abundance shows 21,283 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight KIRC, HNSC, and GBM as cancer lineages where DNTTIP1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for DNTTIP1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes DNTTIP1 survival associations across molecular data types. DNTTIP1 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (2) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible DNTTIP1 RNA expression–survival associations across cancer types. High DNTTIP1 expression shows unfavorable associations in KIRC, UVM, LIHC, ACC, LAML and LGG. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for DNTTIP1 RNA expression.
This table summarizes DNTTIP1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16, while mass-spec protein shows differences in 7. The strongest signals are observed in HNSC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for DNTTIP1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. DNTTIP1 shows higher tumor expression in HNSC, COAD, KIRC, LUAD, KIRP and LIHC. The HNSC box plot shows higher DNTTIP1 RNA expression in tumor versus normal tissue (log2 FC = +1.000, t-test p < 0.001).
This table shows molecular features associated with DNTTIP1 in patient tissues and cancer cell lines. In patient samples, DNTTIP1 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, DNTTIP1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Myeloma and BREAST.
